Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer

ABACIOGLU M. U., Yumuk P., Caglar H., Sengoz M., Turhal N.

BMC CANCER, vol.5, 2005 (SCI-Expanded, Scopus) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 5
  • Publication Date: 2005
  • Doi Number: 10.1186/1471-2407-5-71
  • Journal Name: BMC CANCER
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Acibadem Mehmet Ali Aydinlar University Affiliated: No

Abstract

Background: Combined chemoradiotherapy (CRT) is the treatment of choice for stage III NSCLC. Gemcitabine (G) is a novel deoxycitidine analogue that has been proven to be a potent radiosensitizer. Twenty-two consecutive patients were treated with concurrent CRT to demonstrate the tolerability and efficacy of low dose G given weekly as radiosensitizer in stage III NSCLC.